⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461345 | 0.96 | ALDH1A1 (0.33) | — | |
| SCHEMBL28452 | 0.95 | — | — | |
| Methane SCHEMBL15557692 | 0.91 | — | — | |
| SCHEMBL22129606 | 0.91 | — | — | |
| SCHEMBL358694 | 0.91 | ALDH1A1 (0.36) | — | |
| SCHEMBL29433608 | 0.91 | — | — | |
| SCHEMBL27057 | 0.91 | — | — | |
| SCHEMBL22129579 | 0.91 | ALDH1A1 (0.36) | — | |
| Ammonia Solution, Strong SCHEMBL7889887 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL25254922 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3385308-B1 | POLYESTER-BASED RESIN COMPOSITION AND PRODUCTION PROCESS THEREFOR, MOLDED OBJECT AND PRODUCTION PROCESS THEREFOR, AND MASTERBATCH | MITSUBISHI GAS CHEMICAL CO (JP) | 2021-02-24 | — | — | EP | disclosed |
| EP-3545042-A1 | CURABLE COMPOSITIONS | Arkema France (FR) | 2019-10-02 | — | — | EP | disclosed |
| EP-3496943-A1 | COMPOUNDS CONTAINING CYCLIC STRUCTURAL ELEMENTS, URETHANE/UREIDO LINKAGES AND A FREE RADICAL-POLYMERIZABLE FUNCTIONAL GROUP | Arkema France (FR) | 2019-06-19 | — | — | EP | disclosed |
| WO-2018095823-A1 | CURABLE COMPOSITIONS | ARKEMA FRANCE (FR) | 2018-05-31 | — | — | WO | disclosed |
| EP-3314005-A1 | TREATMENT OF NUT MIDLINE CARCINOMA | Tensha Therapeutics, Inc. (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-3286192-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co KG (DE) | 2018-02-28 | — | — | EP | disclosed |
| WO-2018028903-A1 | COMPOUNDS CONTAINING CYCLIC STRUCTURAL ELEMENTS, URETHANE/UREIDO LINKAGES AND A FREE RADICAL-POLYMERIZABLE FUNCTIONAL GROUP | ARKEMA FRANCE (FR) | 2018-02-15 | — | — | WO | disclosed |
| WO-2017177004-A1 | TERTIARY AMIDES AND METHOD OF USE | ABBVIE INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| EP-3212184-A1 | SUBSTITUTED TETRAHYDROPYRANS AND METHOD OF USE | Abbvie S.a.r.l. (LU) | 2017-09-06 | — | — | EP | disclosed |
| EP-3212189-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | AbbVie S.À.R.L. (LU) | 2017-09-06 | — | — | EP | disclosed |
| WO-2004060893-A1 | PYRROLOPYRIDINE POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004037769-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1392655-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003099266-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-1358160-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003089404-A1 | NAPHTHALENE AMIDES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2003-10-30 | — | — | WO | disclosed |
| EP-1250332-A1 | INHIBITORS OF INTERLEUKIN 5 GENE EXPRESSION | Abbott Laboratories (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2002062762-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062761-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
| WO-2001044223-A1 | INHIBITORS OF INTERLEUKIN 5 GENE EXPRESSION | ABBOTT LABORATORIES (US) | 2001-06-21 | — | — | WO | disclosed |